The combination of a BRAF V600E inhibitor plus a downstream MEK inhibitor avoids paradoxical activation of the MAPK pathway in normal tissues, reducing the risk of skin tumors while enhancing pathway inhibition within BRAF mutant tumors [12, 13]. The gene discussed is MAP2K7; the disease is skin neoplasm.